The ECOG-ACRIN E1910 study assessed the benefit of blinatumomab for BCR::ABL1 negative B-lineage acute lymphoblastic leukaemia (ALL) patients who become measurable residual disease negative (<0.01%) after induction chemotherapy. In this touchONCOLOGY interview, we speak with Dr Mark Litzow (Mayo Clinic, Rochester, MN, USA) to discuss the findings of the study and their impact on the treatment paradigm for BCR::ABL1 negative ALL.
The abstract entitled ‘Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial’ (Abstract #LB-1) was presented at ASH Annual Meeting, 10–13, December, 2022.
Questions:
- What was the rationale for, and design of, the ECOG-ACRIN E1910 study? (0:22)
- What were the findings of the third interim efficacy analysis? (3:54)
- What will be the impact of these findings on the treatment paradigm for BCR::ABL1 negative ALL? (4:52)
Disclosures: Mark Litzow has received grant/research support from Amgen.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ASH 2022
Access more content on Haematological Malignancies and Leukaemia
